GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (Cannabidiol) In The Treatment …

  • Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo
  • Today’s data represents the third positive Phase 3 pivotal trial for Epidiolex reported in 2016
  • Data reinforce the potential of Epidiolex to be an important new medicine for patients who suffer from this treatment-resistant childhood-onset epilepsy
  • Company to hold investor conference call today at 8:00 a.m. EDT/13:00 BST

London, UK (GLOBE NEWSWIRE) – GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. In this trial, Epidiolex, when added to the patient’s current treatment, achieved the primary endpoint for both dose levels with

... read more at: